Gemma Analysis File of Drug-Induced Lung Injury

Expert Opinion for Analysis of Big Data
1. Auflage 2024
ISBN: 978-981-97-3446-7
Verlag: Springer Singapore
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 116 Seiten

Reihe: Medicine (R0)

This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus,  summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Gemma, Akihiko

Inhaltsverzeichnis

Part I Understanding Drug-Induced Lung Injuries.- 1 Understanding Drug-Induced Lung Injuries.- Part 2 Actual Practice in Drug-Induced Lung Injuries of Each Drug.- 2 EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib).- 3 Anti-EGFR antibodies (cetuximab, panitumumab, necitumumab).- 4 mTOR inhibitors (temsirolimus, everolimus).- 5 Proteasome inhibitor (bortezomib).- 6 Immune checkpoint inhibitors (nivolumab, pembrolizumab, atezolizumab, durvalumab).- 7 Neoangiogenesis inhibitors (sunitinib, sorafenib, bevacizumab).- 8 Other molecular targeted drugs (crizotinib, alectinib, etc.).- 9 Antibody-drug conjugates (ADC) (trastuzumab emtansine, trastuzumab deruxtecan).- 10 Anti-cancer drugs (TS-1, taxanes, CPT-11, platinum-containing drugs, etc.).

Über Autor(innen)

Akihiko GemmaPresident, Nippon Medical School
1983: Graduated from the Faculty of Medicine of Nippon Medical School1986: Served as a trainee doctor in the Pathology Department of the National Cancer Center Research Institute1989: Graduated from Nippon Medical School Graduate School1995: Studied at National Cancer Institute of National Institutes of Health (NIH), the United States1998: Appointed as a lecturer to Nippon Medical School2004: Appointed as an associate professor2008: Appointed as a senior professor to the Department of Medicine (Respiratory, Infectious Disease and Oncology Division)2012: Appointed as a professor to the Graduate School of Medicine in charge of respiratory medicine2013: Appointed dean of Department of Medicine2015: Appointed president